ArticleIntensive care medicine experimental2026
Evaluation of plasma calprotectin as a marker for infection in various clinical settings: a prospective observational study.
Article in Intensive care medicine experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReliably distinguishing infection from sterile inflammation is a major clinical challenge. Uncertainty can lead to unnecessary courses of antibiotics, fueling antimicrobial resistance and adverse effects. Calprotectin, a biomarker released by activated immune cells, may inform decision-making.
methodsThis prospective, observational, single-centre study recruited patients with suspected infection who provided blood samples on enrolment from the Emergency Department (ED) and Intensive Care Unit (ICU) of a central London university hospital. A separate longitudinal study with five days' blood sampling was performed in patients undergoing elective major non-cardiac surgery, in whom infection was adjudicated according to the Standardised Endpoints in Perioperative Medicine (StEP) initiative. Diagnostic adjudication was performed blinded to calprotectin. The primary outcome was the ability of calprotectin to diagnose infection. Secondary outcomes included a comparison to C-reactive protein (CRP).
results427 patients were included, of whom 186 (44%) were female. Of 245 ED patients, 71 (29%) had active cancer and 56 (23%) were on immunosuppressants. The median calprotectin level in the no-infection group was 1.97 mg/L (IQR 1.02-3.39), compared to 2.76 (IQR 1.65-5.08) mg/L in low-probability infection, 2.63 mg/L (IQR 1.83-5.23) in high-probability infection, and 2.64 mg/L (IQR 1.49-4.45) in patients with confirmed infection. Ordinal regression analysis found no meaningful association between calprotectin levels and infection, or bacterial infection. Logistic regression showed an unadjusted AUC of 0.53 (95%-CI 0.45-0.62) for calprotectin and a binary outcome of infection compared to an AUC of 0.63 (95%-CI 0.55-0.71) for CRP. Similar results were seen in a sensitivity analysis excluding patients with cancer or immunosuppression. In 98 ICU patients, neither calprotectin nor CRP showed a meaningful association with an adjudicated diagnosis of infection or ICU death. In the peri-operative cohort, calprotectin levels remained elevated over 5 days, but with no difference between patients developing or not developing infection.
conclusionCalprotectin showed only limited ability to differentiate infection from inflammation across ED, ICU, and elective surgery patients. Excluding patients with cancer or immunosuppression did not alter the overall findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.